Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularORALStandard

NYSTATIN

NYSTATIN

Standard Dose
100,000 UNITS/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview NYSTATIN is listed in Drugs@FDA under application 214346 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient NYSTATIN Form and strength SUSPENSION;ORAL - 100,000 UNITS/ML Sponsor SENORES PHARMS Submission history Latest submission status date: 2022-03-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview NYSTATIN is listed in Drugs@FDA under application 214346 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient NYSTATIN Form and strength SUSPENSION;ORAL - 100,000 UNITS/ML Sponsor SENORES PHARMS Submission history Latest submission status date: 2022-03-10 00:00:00. Submission type: ORIG.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.